Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Monday, May 1, 2006

Approximately 30% of patients with an episode of adequately treated deep venous thrombosis (DVT) develop post-thrombotic syndrome (PTS) within 2 years. Studies have shown that the average patient treated with warfarin spends only 60% of the time in his or her goal international normalized ratio (INR) range of 2.0 to 3.0. A recent investigation of the relationship between subtherapeutic INRs and PTS demonstrated that patients who spent more than 50% of their time below an INR of 2.0 had an almost 3-fold risk of developing PTS. Patients in this study were treated with warfarin for at least 3 months and were followed for a maximum of 5 years to assess for signs, symptoms, and severity of PTS.

The authors concluded that low-quality treatment with warfarin is related to the occurrence of PTS in patients with DVT. Strategies aimed at improving the quality of long-term anticoagulation may have the potential to reduce the incidence of this complication.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues